SCHEDULE 13G/A: SCHEDULE 13G/A – Description

• Post author:andrewkaretas
• Post published:August 8, 2025
• Post category:SEC Filings

Allogene Therapeutics, Inc.

Continue ReadingSCHEDULE 13G/A: SCHEDULE 13G/A – Description

Allogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update

• Post author:andrewkaretas
• Post published:August 6, 2025
• Post category:Latest News

Conference Call and Webcast Scheduled for August 13, 2025 at 2:00 p.m. PT / 5:00 p.m. ET SOUTH SAN FRANCISCO, Calif. , Aug. 06, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics…

Continue ReadingAllogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update

8-K: Report of unscheduled material events or corporate event

• Post author:andrewkaretas
• Post published:August 1, 2025
• Post category:SEC Filings

Allogene Therapeutics, Inc.

Continue Reading8-K: Report of unscheduled material events or corporate event

Allogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation for Large B-Cell Lymphoma

• Post author:andrewkaretas
• Post published:August 1, 2025
• Post category:Latest News

Lymphodepletion Regimen Selection Made in Conjunction with the ALPHA3 Data and Safety Monitoring Board (DSMB) and Steering Committee , and in Consultation with the FDA Following an ALLO-647-Related Death in the…

Continue ReadingAllogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation for Large B-Cell Lymphoma

SCHEDULE 13G: SCHEDULE 13G – Description

• Post author:andrewkaretas
• Post published:July 16, 2025
• Post category:SEC Filings

Allogene Therapeutics, Inc.

Continue ReadingSCHEDULE 13G: SCHEDULE 13G – Description

4: Statement of changes in beneficial ownership of securities

• Post author:andrewkaretas
• Post published:June 23, 2025
• Post category:SEC Filings

Allogene Therapeutics, Inc.

Continue Reading4: Statement of changes in beneficial ownership of securities

ALLO-316 in Advanced Clear Cell Renal Cell Carcinoma: Updated Results From the Phase 1 TRAVERSE Study

• Post author:andrewkaretas
• Post published:June 1, 2025
• Post category:CD70/Scientific Publications

Continue ReadingALLO-316 in Advanced Clear Cell Renal Cell Carcinoma: Updated Results From the Phase 1 TRAVERSE Study

ALPHA3: A Pivotal Phase 2 Study of First‑Line (1L) Consolidation With Cemacabtagene Ansegedleucel (Cema‑Cel) in Patients (Pts)  With Large B‑Cell Lymphoma (LBCL) and Minimal Residual Disease (MRD)  After Response to Standard Therapy

• Post author:andrewkaretas
• Post published:June 1, 2025
• Post category:CD19/Scientific Publications

Continue ReadingALPHA3: A Pivotal Phase 2 Study of First‑Line (1L) Consolidation With Cemacabtagene Ansegedleucel (Cema‑Cel) in Patients (Pts)  With Large B‑Cell Lymphoma (LBCL) and Minimal Residual Disease (MRD)  After Response to Standard Therapy

“Off-the-shelf” CAR T—New frontiers in autoimmune disease

• Post author:andrewkaretas
• Post published:May 7, 2025
• Post category:Perspectives

Continue Reading“Off-the-shelf” CAR T—New frontiers in autoimmune disease

Allogeneic Chimeric Antigen Receptor T‑Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B‑Cell Lymphoma: Phase I Experience From the ALPHA2/ALPHA Clinical Studies

• Post author:andrewkaretas
• Post published:February 12, 2025
• Post category:CD19/Scientific Publications

Continue ReadingAllogeneic Chimeric Antigen Receptor T‑Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B‑Cell Lymphoma: Phase I Experience From the ALPHA2/ALPHA Clinical Studies